MacroGenics Announces CEO Transition Amidst Strong Growth
Company Announcements

MacroGenics Announces CEO Transition Amidst Strong Growth

The latest announcement is out from MacroGenics ( (MGNX) ).

MacroGenics, a biopharmaceutical company known for its innovative cancer therapies, announced the upcoming departure of Dr. Scott Koenig as CEO, effective February 2025. The company is set to begin its search for a new leader, with Dr. Koenig remaining as an advisor. Under his leadership, MacroGenics achieved significant milestones, including FDA approvals for several therapies. The transition comes as the company continues to develop a robust pipeline of promising treatments and maintains a strong financial position.

Learn more about MGNX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyMacroGenics downgraded to Market Perform from Outperform at JMP Securities
TheFlyMacroGenics Margenza rights sale a positive, says Leerink
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App